#65 Notable Clinical Interest
Emerging findings or policy developments worth monitoring closely.
Clinicians treating children with drug-resistant epilepsy need to understand the access barriers their patients face, as NHS provision of medical cannabis remains limited despite legal authorization and evidence supporting its use in this population. This campaign highlights a critical gap between regulatory approval and clinical availability that directly impacts treatment options for families exhausting conventional antiepileptic medications. Awareness of these access limitations helps clinicians better counsel patients and families about realistic pathways to care, including potential private prescribing routes or clinical trial participation.
A campaign has been launched to address ongoing barriers to NHS access for medical cannabis in children with drug-resistant epilepsy, a condition where conventional antiepileptic drugs have failed. Despite legal changes in the UK that permit specialist prescription of cannabis-based medicinal products, systemic obstacles including limited NHS funding, specialist availability, and restrictive commissioning arrangements continue to prevent eligible pediatric patients from obtaining treatment. The campaign highlights that while cannabis-derived cannabidiol has demonstrated efficacy in reducing seizures in certain forms of drug-resistant epilepsy, most affected children remain unable to access this option through the public healthcare system and must rely on private prescriptions or unregulated products. These access barriers represent a significant gap between legal authorization and clinical availability, leaving families with limited options for managing severe, treatment-refractory seizure disorders. Clinicians should be aware that although they may now legally prescribe medical cannabis for eligible pediatric epilepsy patients, practical implementation through NHS commissioning remains inconsistent across regions. Patients and families should advocate with their specialists and commissioning bodies about access pathways, while clinicians should document clinical need clearly to support funding requests where medical cannabis is deemed appropriate.
“What we’re seeing with these children is that conventional anticonvulsants have failed them, and the evidence for cannabidiol in drug-resistant epilepsy is robust enough that we should have a clear pathway to access it rather than forcing families into the position of choosing between the black market and bankruptcy. The real clinical failure here isn’t the medicine, it’s the policy that prevents doctors from offering it.”
🧠 While the clinical evidence for cannabinoid-based medicines in drug-resistant epilepsy has strengthened in recent years, with products like epidiolex showing efficacy in specific seizure syndromes, access remains significantly limited by NHS funding constraints, prescribing restrictions, and the high cost of pharmaceutical-grade formulations. The gap between clinical evidence and real-world availability creates an inequitable situation where families with resources may pursue private prescriptions or travel abroad, while others cannot access potentially beneficial treatment. Confounding factors include the heterogeneity of “drug-resistant epilepsy” as a diagnosis, the variable quality and cannabinoid profiles of different products, and limited long-term safety data in pediatric populations, which reasonably inform cautious prescribing guidelines. Healthcare providers should be aware that some patients and families are seeking medical cannabis through unregulated channels when faced with NHS barriers, exposing them to quality and safety risks.
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it: